000277795 001__ 277795
000277795 005__ 20250423100224.0
000277795 0247_ $$2doi$$a10.1038/s41467-025-58132-7
000277795 0247_ $$2pmid$$apmid:40140380
000277795 037__ $$aDZNE-2025-00473
000277795 041__ $$aEnglish
000277795 082__ $$a500
000277795 1001_ $$00000-0002-5768-4277$$aMathiopoulou, Varvara$$b0
000277795 245__ $$aGamma entrainment induced by deep brain stimulation as a biomarker for motor improvement with neuromodulation.
000277795 260__ $$a[London]$$bSpringer Nature$$c2025
000277795 3367_ $$2DRIVER$$aarticle
000277795 3367_ $$2DataCite$$aOutput Types/Journal article
000277795 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1743172443_5909
000277795 3367_ $$2BibTeX$$aARTICLE
000277795 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277795 3367_ $$00$$2EndNote$$aJournal Article
000277795 520__ $$aFinely tuned gamma (FTG) oscillations from the subthalamic nucleus (STN) and cortex in Parkinson's disease (PD) patients undergoing deep brain stimulation (DBS) are often associated with dyskinesia. Recently it was shown that DBS entrains gamma activity at 1:2 of the stimulation frequency; however, the functional role of this signal is not yet fully understood. We recorded local field potentials from the STN in 19 chronically implanted PD patients on dopaminergic medication during DBS, at rest, and during repetitive movements. Here we show that high-frequency DBS induced 1:2 gamma entrainment in 15/19 patients. Spontaneous FTG was present in 8 patients; in five of these patients dyskinesia occurred or were enhanced with entrained gamma activity during stimulation. Further, there was a significant increase in the power of 1:2 entrained gamma activity during movement in comparison to rest, while patients with entrainment had faster movements compared to those without. These findings argue for a functional relevance of the stimulation-induced 1:2 gamma entrainment in PD patients as a prokinetic activity that, however, is not necessarily promoting dyskinesia. DBS-induced entrainment can be a promising neurophysiological biomarker for identifying the optimal amplitude during closed-loop DBS.
000277795 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000277795 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000277795 650_7 $$2NLM Chemicals$$aBiomarkers
000277795 650_2 $$2MeSH$$aHumans
000277795 650_2 $$2MeSH$$aDeep Brain Stimulation: methods
000277795 650_2 $$2MeSH$$aParkinson Disease: therapy
000277795 650_2 $$2MeSH$$aParkinson Disease: physiopathology
000277795 650_2 $$2MeSH$$aSubthalamic Nucleus: physiopathology
000277795 650_2 $$2MeSH$$aMale
000277795 650_2 $$2MeSH$$aFemale
000277795 650_2 $$2MeSH$$aMiddle Aged
000277795 650_2 $$2MeSH$$aAged
000277795 650_2 $$2MeSH$$aGamma Rhythm: physiology
000277795 650_2 $$2MeSH$$aBiomarkers
000277795 650_2 $$2MeSH$$aDyskinesias: physiopathology
000277795 650_2 $$2MeSH$$aDyskinesias: therapy
000277795 650_2 $$2MeSH$$aDyskinesias: etiology
000277795 7001_ $$aHabets, Jeroen$$b1
000277795 7001_ $$00000-0003-1290-208X$$aFeldmann, Lucia K$$b2
000277795 7001_ $$00000-0002-1280-5928$$aBusch, Johannes L$$b3
000277795 7001_ $$aRoediger, Jan$$b4
000277795 7001_ $$aBehnke, Jennifer K$$b5
000277795 7001_ $$aSchneider, Gerd-Helge$$b6
000277795 7001_ $$aFaust, Katharina$$b7
000277795 7001_ $$0P:(DE-2719)2811089$$aKühn, Andrea$$b8$$eLast author$$udzne
000277795 773__ $$0PERI:(DE-600)2553671-0$$a10.1038/s41467-025-58132-7$$gVol. 16, no. 1, p. 2956$$n1$$p2956$$tNature Communications$$v16$$x2041-1723$$y2025
000277795 8564_ $$uhttps://pub.dzne.de/record/277795/files/DZNE-2025-00473.pdf$$yOpenAccess
000277795 8564_ $$uhttps://pub.dzne.de/record/277795/files/DZNE-2025-00473.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000277795 909CO $$ooai:pub.dzne.de:277795$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000277795 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811089$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000277795 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000277795 9141_ $$y2025
000277795 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000277795 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNAT COMMUN : 2022$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT COMMUN : 2022$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-01-30T07:48:07Z
000277795 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-01-30T07:48:07Z
000277795 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000277795 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000277795 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2024-01-30T07:48:07Z
000277795 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)1060$$2StatID$$aDBCoverage$$bCurrent Contents - Agriculture, Biology and Environmental Sciences$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2025-01-02
000277795 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000277795 9201_ $$0I:(DE-2719)5000008$$kAG Kühn$$lMovement Disorders (Parkinson's disease, Dystonia)$$x0
000277795 980__ $$ajournal
000277795 980__ $$aVDB
000277795 980__ $$aUNRESTRICTED
000277795 980__ $$aI:(DE-2719)5000008
000277795 9801_ $$aFullTexts